KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Acquisitions: 2023-2025

  • Regeneron Pharmaceuticals' Acquisitions was N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.4 million, marking a year-over-year change of. This contributed to the annual value of $16.5 million for FY2024, which is 69.95% down from last year.
  • Regeneron Pharmaceuticals' Acquisitions amounted to $3.0 million in Q3 2025, which was down 73.91% from $11.5 million recorded in Q4 2024.
  • In the past 5 years, Regeneron Pharmaceuticals' Acquisitions registered a high of $51.1 million during Q3 2023, and its lowest value of $3.0 million during Q3 2025.
  • In the last 3 years, Regeneron Pharmaceuticals' Acquisitions had a median value of $7.7 million in 2023 and averaged $17.4 million.
  • Data for Regeneron Pharmaceuticals' Acquisitions shows a peak YoY soared of 202.63% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Regeneron Pharmaceuticals' Acquisitions stood at $3.8 million in 2023, then surged by 202.63% to $11.5 million in 2024, then reached $3.0 million in 2025.
  • Its Acquisitions stands at $3.0 million for Q3 2025, versus $11.5 million for Q4 2024 and $3.8 million for Q4 2023.